Erdélyi L - Search Results

1

Concentration-Dependent Antibacterial Activity of Chitosan on Lactobacillus plantarum.

Kovács R, Erdélyi L, Fenyvesi F, Balla N, Kovács F, Vámosi G, Klusóczki Á, Gyöngyösi A, Bácskay I, Vecsernyés M, Váradi J. Kovács R, et al. Among authors: erdelyi l. Pharmaceutics. 2022 Dec 21;15(1):18. doi: 10.3390/pharmaceutics15010018. Pharmaceutics. 2022. PMID: 36678647 Free PMC article.

2

Investigation of the Role and Effectiveness of Chitosan Coating on Probiotic Microcapsules.

Erdélyi L, Fenyvesi F, Gál B, Haimhoffer Á, Vasvári G, Budai I, Remenyik J, Bereczki I, Fehér P, Ujhelyi Z, Bácskay I, Vecsernyés M, Kovács R, Váradi J. Erdélyi L, et al. Polymers (Basel). 2022 Apr 20;14(9):1664. doi: 10.3390/polym14091664. Polymers (Basel). 2022. PMID: 35566837 Free PMC article.

3

CRRT Is More Than Just Continuous Renal Replacement Therapy.

Erdélyi L, Trásy D. Erdélyi L, et al. Pharmaceuticals (Basel). 2024 Nov 22;17(12):1571. doi: 10.3390/ph17121571. Pharmaceuticals (Basel). 2024. PMID: 39770412 Free PMC article. Review.

4

V2 vasopressin receptor mutations: future personalized therapy based on individual molecular biology.

Erdélyi LS, Hunyady L, Balla A. Erdélyi LS, et al. Front Endocrinol (Lausanne). 2023 May 24;14:1173601. doi: 10.3389/fendo.2023.1173601. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37293495 Free PMC article. Review.

5

Functional Rescue of a Nephrogenic Diabetes Insipidus Causing Mutation in the V2 Vasopressin Receptor by Specific Antagonist and Agonist Pharmacochaperones.

Szalai L, Sziráki A, Erdélyi LS, Kovács KB, Tóth M, Tóth AD, Turu G, Bonnet D, Mouillac B, Hunyady L, Balla A. Szalai L, et al. Among authors: erdelyi ls. Front Pharmacol. 2022 Jan 25;13:811836. doi: 10.3389/fphar.2022.811836. eCollection 2022. Front Pharmacol. 2022. PMID: 35153784 Free PMC article.

6

Correction: Improved Methodical Approach for Quantitative BRET Analysis of G Protein Coupled Receptor Dimerization.

Szalai B, Hoffmann P, Prokop S, Erdélyi L, Várnai P, Hunyady L. Szalai B, et al. Among authors: erdelyi l. PLoS One. 2016 May 31;11(5):e0156824. doi: 10.1371/journal.pone.0156824. eCollection 2016. PLoS One. 2016. PMID: 27243812 Free PMC article.

7

Mutation in the V2 vasopressin receptor gene, AVPR2, causes nephrogenic syndrome of inappropriate diuresis.

Erdélyi LS, Mann WA, Morris-Rosendahl DJ, Groß U, Nagel M, Várnai P, Balla A, Hunyady L. Erdélyi LS, et al. Kidney Int. 2015 Nov;88(5):1070-8. doi: 10.1038/ki.2015.181. Epub 2015 Jul 1. Kidney Int. 2015. PMID: 26131744 Free article.

8

Investigation of the fate of type I angiotensin receptor after biased activation.

Szakadáti G, Tóth AD, Oláh I, Erdélyi LS, Balla T, Várnai P, Hunyady L, Balla A. Szakadáti G, et al. Among authors: erdelyi ls. Mol Pharmacol. 2015 Jun;87(6):972-81. doi: 10.1124/mol.114.097030. Epub 2015 Mar 24. Mol Pharmacol. 2015. PMID: 25804845 Free PMC article.

9

Improved methodical approach for quantitative BRET analysis of G Protein Coupled Receptor dimerization.

Szalai B, Hoffmann P, Prokop S, Erdélyi L, Várnai P, Hunyady L. Szalai B, et al. Among authors: erdelyi l. PLoS One. 2014 Oct 17;9(10):e109503. doi: 10.1371/journal.pone.0109503. eCollection 2014. PLoS One. 2014. PMID: 25329164 Free PMC article.

10

Altered agonist sensitivity of a mutant v2 receptor suggests a novel therapeutic strategy for nephrogenic diabetes insipidus.

Erdélyi LS, Balla A, Patócs A, Tóth M, Várnai P, Hunyady L. Erdélyi LS, et al. Mol Endocrinol. 2014 May;28(5):634-43. doi: 10.1210/me.2013-1424. Epub 2014 Mar 14. Mol Endocrinol. 2014. PMID: 24628417 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

59 results

Search Page

Filters